16.88 +0.22 (1.32%)
Pre-market: 8:00AM EST
|Bid||16.60 x 800|
|Ask||17.17 x 1100|
|Day's range||16.25 - 16.88|
|52-week range||15.02 - 25.31|
|Beta (3Y monthly)||1.74|
|PE ratio (TTM)||8.52|
|Earnings date||10 Feb 2020 - 14 Feb 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||24.36|
Exelixis (EXEL) delivered earnings and revenue surprises of 55.00% and 18.97%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
In this article we are going to estimate the intrinsic value of Exelixis, Inc. (NASDAQ:EXEL) by taking the foreast...
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Calithera (CALA) completes patient enrollment in a phase II study evaluating a combination regimen of its lead candidate, telaglenastat, in patients with advanced kidney cancer.
Seattle Genetics (SGEN) and Astellas' enfortumab vedotin in combination with Merck's Keytruda proves safety in a phase I study as a first-line treatment for advanced bladder cancer. Shares up.
Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio in combination with Inlyta gets positive CHMP recommendation for first-line treatment of advanced kidney cancer.
Exelixis, Inc. (NASDAQ:EXEL) is a stock with outstanding fundamental characteristics. When we build an investment...
Exelixis (EXEL) delivered earnings and revenue surprises of 8.70% and 5.01%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Exelixis' (EXEL) second-quarter 2019 results are expected to benefit from increase in Cabometyx sales. Investors will focus on other pipeline updates as well.
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
For many, the main point of investing in the stock market is to achieve spectacular returns. While not every stock...